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Background: As biobanks play an increasing role in the genomic research that will lead to precision medicine, input
from diverse and large populations of patients in a variety of health care settings will be important in order to successfully
carry out such studies. One important topic is participants’ views towards consent and data sharing, especially since the
2011 Advanced Notice of Proposed Rulemaking (ANPRM), and subsequently the 2015 Notice of Proposed Rulemaking (NPRM)
were issued by the Department of Health and Human Services (HHS) and Office of Science and Technology Policy (OSTP).
These notices required that participants consent to research uses of their de-identified tissue samples and most clinical
data, and allowing such consent be obtained in a one-time, open-ended or “broad” fashion. Conducting a survey across
multiple sites provides clear advantages to either a single site survey or using a large online database, and is a potentially
powerful way of understanding the views of diverse populations on this topic.
Methods: A workgroup of the Electronic Medical Records and Genomics (eMERGE) Network, a national consortium of 9
sites (13 separate institutions, 11 clinical centers) supported by the National Human Genome Research Institute (NHGRI)
that combines DNA biorepositories with electronic medical record (EMR) systems for large-scale genetic
research, conducted a survey to understand patients’ views on consent, sample and data sharing for future
research, biobank governance, data protection, and return of research results.
Results: Working across 9 sites to design and conduct a national survey presented challenges in organization, meeting
human subjects guidelines at each institution, and survey development and implementation. The challenges were met
through a committee structure to address each aspect of the project with representatives from all sites.
Each committee’s output was integrated into the overall survey plan. A number of site-specific issues were
successfully managed allowing the survey to be developed and implemented uniformly across 11 clinical
centers.
Conclusions: Conducting a survey across a number of institutions with different cultures and practices is a
methodological and logistical challenge. With a clear infrastructure, collaborative attitudes, excellent lines of
communication, and the right expertise, this can be accomplished successfully.
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Surveys have been widely utilized to elicit perceptions
about health research and perspectives on issues relevant
to health research policy. Given the important ethical,
legal, and social implications (ELSI) challenges raised by
genomics research, hundreds of surveys have been
conducted with the aim of informing the analysis of
ethics and health policy challenges (see Garrison, et. al.
[1] for a review). While these challenges are important
on national and international scales, most of these sur-
veys have been conducted at single sites or using large
online databases of participants willing to participate in
surveys. Both of these approaches have significant limi-
tations, including lack of generalizability, sampling bias,
and lack of population diversity.
Given variation in local populations and the potential
influence of community relationships with local institu-
tions, development and implementation of surveys across
a variety of populations from multiple institutions helps
address these limitations. However, few surveys relating to
the ELSI challenges of genomic research and particular
participant preferences for consent in genomic research
have been designed and implemented in a collaborative
fashion across multiple sites [2–5].
Technical and organizational challenges are likely
responsible for the relative paucity of multi-institutional
studies on these topics, including diverse cultures at
different institutions; particularly medical centers and
academic health care centers, varying interpretations of
human subjects guidelines, and acceptable practices
regarding data collection from potential participants. In
addition, researchers have their own preferred approaches
to survey development and data collection.
Online databases of potential survey respondents, such
as GfK (http://www.knowledgenetworks.com/ganp/), a
database of US households that are continuously sur-
veyed through an online format, are important alter-
natives to multi-site surveys but are often limited to
participants with online access. Another approach to
obtaining an informative sample of participants would
be to identify patients who receive care in health care
settings where research is conducted, and then broadly
survey patients at those institutions. In order to obtain
a sample that includes participants with diverse expe-
riences and characteristics, however, it would be
necessary to survey patients across a diverse set of
health care institutions. Surveying large numbers of
patients from several institutions would enable com-
parisons across different types of care settings and
patient backgrounds that might not be possible using
GfK. In this case, conducting a survey across multiple
sites provides clear advantages to either a single site
survey, using a large online database, or commercially
available sampling frames.The eMERGE (Electronic Medical Records and
Genomics) Network undertook such a challenge in
2013. The eMERGE Network was initiated by the
National Human Genome Research Institute (NHGRI)
in 2007 (RFA HG-07-005) to “develop, disseminate,
and apply approaches to research that combine DNA
biorepositories with electronic medical record (EMR)
systems for large-scale, high-throughput genetic re-
search” [6]. A focus of eMERGE II, initiated in 2011
(RFA-HG-10-009, RFA-HG-10-010, RFA-HG-11-022),
was to explore the implementation of genomic medi-
cine, how genetic variants could be incorporated into
the EMR for clinical use, and the impact on clinical
care and patients. The 9 eMERGE sites (which
included 13 institutions, 11 of which are clinical cen-
ters) were: Northwestern University (NU), Vanderbilt
University Medical Center (VU), Group Health (GHC)
and University of Washington (UW), Mayo Clinic
(Mayo), Geisinger Health Care (GHC), Icahn School
of Medicine at Mount Sinai (ISMMS), Children’s
Hospital of Philadelphia (CHOP), Boston Children’s
Hospital (BCH) and Cincinnati Children’s Hospital
Medical Center (CCHMC), and Marshfield Clinic
(MC), Essentia Rural Health Institute (ERHI) and
Penn State. The Coordinating Center (CC) was at VU.
Issues around Consent, Education, Regulation, and
Consultation (CERC) were addressed by the eMERGE
CERC workgroup [7]. The CERC workgroup’s efforts
were aimed at understanding patients’ views and atti-
tudes about participation in genomic research, particu-
larly when that research relies on close linkages with
EMRs. In 2013, the eMERGE network received a supple-
mental NIH grant aimed at understanding how the
policy changes proposed in the 2011 Advanced Notice of
Proposed Rulemaking (ANPRM) for revisions to the
Common Rule released by the Department of Health
and Human Services (HHS) and the Office of Science
and Technology Policy (OSTP) would affect research
participation at institutions, like those in the eMERGE
Network, where genomic biorepository research takes
place [8]. The ANPRM changes aimed to improve pro-
tections for human subjects while facilitating research
and reducing burden on investigators. The subsequent
Notice of Proposed Rulemaking (NPRM), issued in
September 2015 [9], included many of the same policy
proposals raised in the ANPRM. Among the NPRM
proposals is the recommendation to require informed
consent for research using de-identified tissue samples
and most clinical data, and that such consent can be
obtained in a one-time, open-ended or “broad” fashion.
Broad consent can be defined as a process in which
participants agree prospectively to have their samples,
genomic data, and/or health information retained for
use in any future research deemed appropriate by the
Table 1 Committee name and leadership of each committee
Committee name Committee leads
IRB Protocol Jen McCormick and Sharon Aufox
Cognitive Interviews Melanie Myers
Systematic Literature Review Nanibaa’ Garrison
Survey Development Saskia Sanderson
Sampling Strategies Jonathan Schildcrout
Data Management Kyle Brothers
Survey Analysis Jonathan Schildcrout
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Policy requires obtaining consent for data sharing as a
condition for funding of most genomics research. These
policies will greatly affect research using biobanks.
Although much has been written about the use of
broad consent for biobanking and the future use of sam-
ples, empirical research suggests most patients do not
favor broad consent over other consent options [1] and
that factors such as privacy and distrust, which may
affect willingness to participate, are greater for minority
participants [1, 10–12]. However, less is known about
sociodemographic factors; such as SES, education, and
rural and non-rural living, which may affect willingness
to participate in a biobank and allow one’s sample and
data to be used for future research (see Garrison et al.
for a full review [1]) Further, the Precision Medicine Ini-
tiative [13] magnifies the importance of informing and
recruiting a large and representative cohort for current
and future genomic research in ways that are acceptable
to patients and the public.
A joint effort across the eMERGE Network, led by the
CERC workgroup, provided an ideal way to address issues
related to sharing of research data and broad consent and
to obtain input from a diverse sample of participants. The
highly collaborative eMERGE Network has a long-
standing track record in productive research [7, 14–18].
The Network included a large population of biobank
participants recruited across a diverse range of health care
settings; including both urban and rural, adult and
pediatric, academic teaching hospitals, an integrated
health system and a member-governed coordinated care
system. Thus a large survey across the 11 clinical centers
that were part of the eMERGE Network was an ideal
venue for eliciting the views of both eMERGE biobank
participants and non-participants on issues around broad
consent. The multi-disciplinary CERC workgroup had
valuable expertise in addressing complex ELSI issues
around genomic research. Within the context of the
ANPRM and its potential impact on patient recruitment
in biobank research, the eMERGE CERC workgroup set
out to examine patients views on broad consent,
governance and oversight of genomic research, and
data sharing. Data sharing can be defined as making
data available to other investigators though managed
or open databases. A subcommittee of the CERC work-
group, the “CERC Survey workgroup”, was organized
with at least one member from each eMERGE institu-
tion and the CC represented on the subcommittee.
In this paper we describe the collaborative effort
among the members of the eMERGE Network CERC
Survey workgroup to fill this important gap in know-
ledge by providing much-needed, large-scale quantitative
data in the form of a survey sent to 90,000 patients and
parents of patients across the 11 eMERGE clinicalcenters. The aims of this paper are to: 1) describe the
process for developing and implementing the survey, 2)
present the specific challenges of conducting a survey
across diverse geographies and populations in a large
network and the methods we developed to meet those
challenges; including an organizational structure, separate
but coordinated IRB approvals, and a survey development
and implementation process that took into consideration
the characteristics at each site.
Methods
The CERC Survey workgroup first created an
organizational structure to carry out the project. Co-chairs
of the CERC workgroup, Maureen Smith (NU) and Ingrid
Holm (BCH), led the effort and were responsible for facili-
tating communication, setting deadlines, disseminating
information (with the CC), working with consultants and
contractors (with the CC), communicating updates to the
eMERGE steering committee, and reporting to the
NHGRI/NIH. (The eMERGE steering committee is com-
prised of the principle investigators from each of the sites.)
The workgroup divided the project into tasks and for each
task established a committee to carry out the task. The
committees and their leaders are listed in Table 1. The
workgroup also engaged external individuals with expertise
in cognitive interviewing methods, and in conducting
biobank consent research, to augment the expertise of its
members. The CERC Survey workgroup conducted
weekly/biweekly conference calls throughout the entire
study period (over 2 years), and each committee held con-
ference calls weekly during periods of their most intense
activity. The CERC Survey workgroup also met in person
three times a year during eMERGE steering committee
meetings.
Systematic literature review
The Systematic Literature Review committee [Lead-
Nanibaa’ Garrison (VU)] conducted a review of the
literature to define gaps in current literature regarding
patients’ acceptance of various forms of consent and
factors associated with willingness to consent. The re-
view focused on studies about broad consent and data
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of results. Database searches were conducted between
October and December 2013 with an update in March
2015. The following databases were used: MEDLINE via
the PubMed interface, Web of Science, National Reference
Center for Bioethics Literature databases (EthxWeb,
GenETHX), and Dissertation Abstracts International.
Survey development
One of the most challenging aspects of the project was
developing the survey itself, led by the Survey Develop-
ment committee [Lead- Saskia Sanderson (ISMMS)].
The survey requirements included that it 1) address the
key, complex issues of broad consent and data sharing, 2)
be relatively short, 3) be written at an 8th grade reading
level, 4) be written in English as we cannot know a priori
which potential participants only read languages other
than English, and 5) be uniformly sent to 100,000 poten-
tial respondents (based on an estimate of 20% undeliver-
able rate, and an expected response rate of 20% for a total
of 16,000 respondents,). Initial power calculations were
based on having sufficient power to stratify analyses by
subgroup. In addition, the CERC members were spread
from Seattle to London (8 time zones), increasing the
logistical challenges.
Population Sampling
The sampling strategy committee [Co leads- Jonathan
Schildcrout (VU) and Nathaniel Mercaldo (VU)] de-
signed the population sampling plan to be implemented
across all 11 clinical centers. Our inclusion criteria in-
cluded patients with a valid address (only one per house-
hold), and at least one inpatient or outpatient contact
with a participating eMERGE clinical site between Sep-
tember 1, 2013 and August 31, 2014, for a population of
approximately 2.4 million individuals. We used a recent
one-year time horizon to minimize the chance that the
patient had moved. Demographic variables (age, gender,
race, and ethnicity) were obtained from the EMR at each
institution even though such data may be not be entirely
accurate and may have varying degrees of availability
across sites. To bolster missing EMR data, and to ensure
ascertainment of other key sociodemographic data, pa-
tient EMR data were linked to US census data files. The
linkage process involved geocoding each patient’s home
address (i.e., converting an address to a latitude and lon-
gitude value) and identifying the corresponding census
block-group identifier using the geocoded address [19].
Geocoded address and Urban Area Criteria data were
used to determine non-rural living while the census
block-group identifier and the data from the American
Community Survey were used to impute missing race,
ethnicity and education [20]. The block-group level is
the most granular level of data that the census provides,thus the block-group level was used to obtain the most
accurate estimates as possible. While geocoding of pa-
tient addresses was done at most sites, addresses for
those sites without the required expertise were geocoded
at the CC, permitted by the eMERGE data sharing
agreement. A stratified sampling plan was developed
where sampling strata were defined using the combined
EMR and Census-imputed sociodemographic variables.
IRB protocol
There were two potential approaches to obtaining IRB
approval. We could have a central IRB in which each in-
stitution cedes review to the central IRB as per a reliance
agreement. Alternatively, we considered obtaining IRB
approval from each of the 11 clinical centers. Since it
was not clear that all sites would cede review to a central
IRB, we decided to obtain IRB approval separately at
each institution. As each IRB submission had to include
an almost identical protocol and identical materials to
be sent to potential participants, a single IRB protocol
was developed by the IRB Protocol committee [Co leads-
Jen McCormick (Mayo) and Sharon Aufox (NU)]. The
committee developed introductory and reminder letters
and postcards. Each site requested a waiver of informed
consent due to minimal risk of the study. Completion
and return of the questionnaire would assume passive
consent. All study documents were submitted to each
institution’s IRB in a coordinated manner.
Cognitive interviews
Once a near-to-final version of the survey was developed,
the Cognitive Interview committee [Lead- Melanie Myers
(CCHMC)] was tasked with conducting cognitive inter-
views to determine whether the questions elicited the
information they were designed to capture [21, 22]. The
committee lead is an experienced qualitative investigator
and she trained the interviewers at the participating sites.
The cognitive interviews focused on the language, com-
prehensibility, decision processes, and relevance of each
item in the survey (unpublished). We planned to conduct
in person interviews with a convenience sample of up to
10 patients (or parents at pediatric sites) at each of 6 sites.
Each cognitive interview was expected to take 60–90 min
and participants would be compensated for their time.
Sites for cognitive interviews were selected for non-white
populations, individuals from rural areas, and having
lower income.
Piloting the survey
The survey was piloted to gather data on responses,
including an evaluation of missed answers, problems
with skip patterns, and straight-lining (selecting the
same response for a series of questions without properly
reading through each item). A total of 1500 individuals
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each institution, a total of either 75 (2 institutions) or
150 (9 institutions) participants were identified by ran-
domly selecting one from each sampling stratum. An initial
survey pre-notice postcard was sent to each individual to
receive the survey, letting them know the survey would be
mailed to them shortly and providing them with contact
information in case they had any questions. The survey
mailing, which included an invitation letter, a non-
contingent pre-incentive $2 bill, a scannable mail question-
naire, and a self-addressed business reply envelope, was
mailed to participants one week later. The invitation letter
provided both a unique identifying number (ID) and a sim-
ple URL, http://www.biobanksurvey.org/, to access the
internet version of the survey. Respondents had the option
to complete the survey on paper or online. Those who
chose to complete the survey online were able to type the
web address into a browser, enter their ID, and complete
the survey through the REDCap survey interface [23].
Survey implementation
In order to examine views of individuals recruited from
multiple institutions across the US without confounding
from between-site methodological differences, we planned
to implement the survey uniformly across the institutions.
We considered alternate methodologies for dissemination,
including an email invitation with a link to a web-based
survey. This would be less costly than a paper survey and
would allow electronic capture of responses. To further
ensure consistency with survey implementation, we
decided to use an outside vendor for survey printing and
mailing. The outside vendor required each site to send
patient contact information (identifiable information) out-
side the institution to the vendor. All sites sought IRB
approval for the vendor and business associates agree-
ments (BAA), as needed.
Results
Systematic literature review
The committee reviewed empirical studies carried out in
the US after 1990 [1] and included studies using a variety
of methodologies, including qualitative, quantitative, and
mixed methods. Demographic characteristics of partici-
pants were reviewed to determine populations that may
not have been included in previous studies. The literature
review was a key component in our hypotheses generation
to define our key survey questions and inform the develop-
ment of the survey and our sampling methodology.
Through the electronic database searches and manual
review of articles and bibliographies, 3,205 relevant cita-
tions and abstracts were found (Fig. 1). After reviewing
titles and abstracts, we excluded 2,714 studies that did not
meet our criteria. We assessed the full text of the 491
remaining studies and excluded another 440 articlesbecause they (i) did not address biobanking, consent, or
data sharing (n = 403); (ii) were not conducted in the
United States (n = 206); or (iii) were not obtainable (n = 1).
Fifty-one publications comprising 48 unique cohorts met
our inclusion criteria. We found that most studies about
consent for biobank participation were small, and that indi-
viduals who were non-Caucasian, of lower income, and/or
less educated were underrepresented. Additionally, the
approach taken by most studies was to offer participants
options about which consent model they preferred. The re-
sults of the systematic literature review informed both the
survey content, design, and the targeted populations for
this study.
Survey development
Informed in part by the results of the literature review,
the Survey Development committee first finalized the
aims and hypotheses and then “operationalized” the aims
by defining the terms and identifying domains of interest
and variables within the aims. The committee developed
a conceptual framework that contained both distal (par-
ticipant level characteristics) and proximal (biobank level
characteristics) variables potentially influencing our pri-
mary outcome. The committee collected surveys from
previous studies, compiled a collection of questions from
these surveys, and chose questions to modify for this
survey. In order to manage this complex task, the com-
mittee divided the task into “domains” and organized
domain subgroups within the committee, each of which
identified survey questions within their domain to bring
back to the group.
One key question that the workgroup needed to address
was the structure of the survey. Based on our conceptual
framework, an important aim of the study was to determine
how proximal influencers, and in particular biobank-level
characteristics – specifically consent approaches and data-
sharing models – would affect willingness to participate in
a biobank. However, previous research had suggested that
survey respondents, when given a choice and asked to com-
pare these types of biobank-level characteristics, may have
difficulty considering practical trade-offs. [24, 25]. These
previous studies have generally found that, when given the
choice, patients tend to favor more restrictive consent and
data-sharing approaches. However, this is not reflective of
the real world. In practice, patients are not given a choice,
but rather are invited to participate in a biorepository for
which a consent and a data-sharing approach have already
been selected. In order to simulate this real-world condi-
tion, and because we had a large population to survey, we
decided to randomize respondents to one of three biobank
scenarios with different consent and data sharing ap-
proaches, and to assess their willingness to participate in
the scenario they were randomized to as the primary out-
come (Table 2). Using this experimental rather than purely
Fig. 1 Survey mailing procedures with times between each step
noted
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ability to manipulate the consent and data sharing features
presented to participants, and conduct between-
participants rather than within-participants comparisons.
Once we made this decision, the committee had to identify
the key constructs that were important to assess, drawing
on the domains identified earlier. The constructs and do-
mains were identified in an iterative process that included
the findings from the systematic literature review as well as
input from outside experts.
Another challenge was how to assess issues relating
not only to adults’ participation in biobank research, but
also issues relating to children’s participation. Three of
the institutions were large pediatric medical centers
(BCH, CCHMC, and CHOP), and one of the challenges
was to determine how to obtain the views of parents
without the need for a separate survey, which could have
been prohibitively costly. Recognizing that many adults
at the non-pediatric centers likely had children less than
18 years of age, we decided that all sites would use the
same survey to elicit adults’ views on themselves and
their youngest child less than 18 years of age.
A final challenge in survey development was to decide
on how the final survey would be sent out. The decisionwas made to send the final survey package to the poten-
tial participants including a cover letter that introduced
and explained the purpose of the study, and general
information required to inform participants about the
survey, their right not to participate, and who to contact
should they have questions. The survey began with one
page providing an explanation of the purpose of the
survey, definitions of terms such as “health information”
and “biobank,” and a detailed description of the purpose
and structure of biobanks that was presented in a
question and answer format. The survey scenario was
presented and followed by the primary question about
willingness to participate in the biobank. Following our
conceptual framework, questions in the following
domains were included in the survey: attitudes towards
taking part in a biobank (perceived benefits, concerns,
information needs), attitudes towards enrolling a child in
a biobank (perceived benefits, concerns), trust in the
healthcare system and medical researchers, privacy
concerns, health-related items, and demographics.
Population sampling
The Systematic Literature Review committee found that,
while the relationships between gender (and to a lesser
degree race) and views on consent and data sharing have
been studied thoroughly, very little was known about the
impact of socioeconomic status, education, rural resi-
dence, age, and ethnicity. Because the eMERGE network
includes 11 large medical centers, we were well posi-
tioned to develop a study design that would enrich the
sample with understudied populations and would there-
fore allow us to examine characteristics associated with
views and attitudes that have not yet been well studied.
After combining EMR data with census data, and
supplementing missing EMR data with census data, we
developed sampling strata based on a cross classification
age (> = 35 or <35 for adult sites, > = 12 or <12 for
pediatric sites), gender, race (white, black, Asian, Native
American, Pacific Islander, other race), ethnicity (Hispanic
or not), education level of adults greater than 25 in the
census block group (<12 years, 12- < 16 years, > =
16 years), and rural residence (yes or no). We then
conducted a disproportionate stratified sampling de-
sign with the goals of oversampling racial and ethnic
minorities, younger adults, those likely to have lower
education, and those living in rural regions. Details of
the sampling strategy will be made available in the
publication of survey results.
IRB protocol
The greatest regulatory challenge was that all changes to
the materials, even if very minor, required all institutions
to change the documents and send an amendment to
their respective IRB since the materials had to be exactly
Table 2 The three consent and data sharing scenarios presented to survey participants
Consent
Type
Data sharing Biobank Description
(All scenarios begin with: Please imagine that you have been asked to allow your health information to be placed
in a biobank at your local hospital or healthcare organization. If you agree to take part in the biobank, the biobank
will share your health information with researchers at your local hospital or healthcare organization who wish to use
the health information in the biobank for research. In addition, this particular biobank will….)
Tiered
Consent
Restricted Database …share your health information with researchers at your local hospital or healthcare organization who wish to use
the health information in the biobank for research. In addition, this particular biobank will also place your health
information in large national databases. This is to make it easier for researchers across the world to do research with
the health information. Researchers from other hospitals, healthcare organizations, companies, and government
agencies concerned with health in the United States and in other countries can apply to use your health information.
When you sign up, you will be asked what types of medical research you will allow your health information to be
used for The biobank will remove your personal information such as name, address, social security number, and birth
date that could identify you before it is shared.
Broad
Consent
Restricted Database …share your health information with researchers at your local hospital or healthcare organization who wish to use
the health information in the biobank for research. In addition, this particular biobank will also place your health
information in large national databases. This is to make it easier for researchers across the world to do research with
the health information. Researchers from other hospitals, healthcare organizations, companies, and government
agencies concerned with health in the United States and in other countries can apply to use your health information.
When you sign up, you will be agreeing for your health information to be used for all kinds of medical research. The
biobank will remove your personal information such as name, address, social security number, and birth date that





…share your health information with researchers at your local hospital or healthcare organization who wish to use
the health information in the biobank for research. In addition, this particular biobank will also place your health
information in a large online database that anyone in the public can access. This is to make it easier for researchers
across the world to do research with the health information. When you sign up, you will be agreeing for your health
information to be used for all kinds of medical research. The biobank will remove your personal information such as
name, address, social security number, and birth date that could identify you before it is shared.
Smith et al. BMC Medical Research Methodology  (2016) 16:162 Page 7 of 11the same at each site. All revisions were compiled by the
IRB Protocol committee and a single final revision was
submitted to all institutions’ IRBs. Although tedious, this
approach proved successful, and final approvals were
received from all institutions’ IRBs prior to conducting
the survey. All institutions’ IRBs approved the waiver of
informed consent.
Another challenge to local and full group IRB approval
grew out of the strategy to use an outside vendor for
survey printing and mailing. The outside vendor required
each site to send patient contact information (identifiable
information) outside the institution to the vendor. With
these requirements having the possibility of creating
delays and disagreement among the various IRBs, site
investigators engaged in pre-emptive conversations with
directors of their IRBs, IRB staff, and representatives from
their institutions’ privacy office. This approach involved 9
of 11 sites signing a HIPAA Business Associate Agreement
(BAA) with the vendor. One institution’s IRB could not
agree to allow patient information to be sent outside the
institution in the absence of patient consent. A strategy to
comply with this local IRB requirement was developed for
one site in which they would address and mail their
surveys themselves. This required additional coordination
in order for the mailings to be sent at the same time as
the vendor mailings.
Timing between the pre-notification postcards and
mailing the full survey was paramount to honoring opt-
out requests. For the first mailing, however, the time be-
tween pre-notification postcards and full survey mailingswas short and a number of individuals received surveys
that had opted out. Most sites filed notification of these
minor violations with their IRB and no further action
was required. One site’s IRB required that the survey
mailing needed to be stopped to allow time to remove
opt-out requests from further survey mailings. This
required all sites to stop mailings until the one IRB
agreed to restart the process.
Cognitive interviews
Forty cognitive interviews were conducted in person
with a convenience sample of up to 10 patients (or
parents at pediatric sites) at each of 6 sites. The survey
was refined in an iterative process, with revised versions
of the survey used in successive rounds of interviews.
Results of the cognitive interviews led to simplifying
language, additional explanations about biobanks, and
rewording of questions about a child’s participation in a
biobank.
Survey data management
Working with an outside vendor for survey administra-
tion had benefits but also challenges. Each institution
required a separate contract with the vendor and the
contracting process at each of the 11 institutions varied
in language, length of time to signed agreement, and in
length of time to paid invoices that were required before
work could proceed.
The vendor printed the postcards and letters with an
institution-specific logo, signature, and contact phone
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mailings. This meant that each institution received and
managed telephone contact with potential participants
or their representatives who had questions about the
study, wanted to opt-out of receiving mailings, or to
report the potential participant’s participation was not
possible (e.g. death). A central REDCap database was
created by the REDCap Database committee [Lead- Kyle
Brothers (CC)] to document all refusals and removals
[23]. This committee also designed an internet survey
that participants could access online using an URL and
access code provided in the invitation letters.
All completed surveys were returned directly to the
vendor who scanned and scored the survey forms. In
addition, the undeliverable mailings sent from the
vendor were also returned to the vendor. Periodic data
files were sent by the vendor to the CC with information
about undeliverable surveys, records for which a paper
survey was received, and the survey responses.
Piloting the survey
In considering the best manner to distribute the
survey, we took into consideration that all sites would
use the same methodology. Although email surveys
would have been less costly, email addresses for
patients were not available at all sites, and some sites
did not find email surveys to be acceptable based on
their interpretation of HIPAA guidelines. Addition-
ally, not all potential participants had access to email,
creating selection bias. Thus one major impact of
having multiple sites was that it constrained our
approach to survey implementation. Ultimately, we
were able to use a mixed-mode design of mail and
internet survey; however, for consistency, all survey
pre-notifications, invitations, and reminders were sent
by mail only.
For the pilot, 1500 surveys were mailed, 5% were un-
deliverable, with 2 opt outs. The response rate was 11%
(there were no follow ups to the initial survey mailing).
Analysis of pilot survey data found few missed answers,
and no problems with straight-lining. While skip
patterns were not an issue, some respondents who had
children over the age of 18 answered the section meant
for participants who had a child under the age of 18. We
therefore added additional language to emphasize the
section was only meant to be answered if the participant
had a child under the age of 18. Based on the small
number of opt out responses, we revised our number of
full surveys to send out to 90,000 potential respondents.
Final survey
The full survey was sent to 90,000 individuals at the 11
institutions following the same procedure used in the
pilot (See Fig. 1). We followed procedures previouslydemonstrated to increase likelihood of response to a
mailed survey [26, 27] including an announcement post-
card, a small incentive ($2), a reminder postcard, a sec-
ond mailing of the survey, and a second reminder
postcard. Thirteen thousand surveys were returned and
available for analysis for a 15.8% response rate. Survey
results are described in detail in another publication. Be-
tween mailings, potential participants could call a local
telephone number to opt-out of receiving further mail-
ings. Opt-out information was reported by each institu-
tion through a central REDCap survey to the CC. The
opt-outs were collated prior to each mailing to remove
names from the list. Due to printing deadlines, it was
not always possible to remove individuals who opted out
from the next mailing. To address this possible issue, in-
dividuals who opted out were advised that they should
ignore and discard any subsequent mailing from the
study. As noted in the IRB Protocol section, an error in
the mailing list for one of the mailings resulted in mail-
ings to some individuals who had previously opted out.
Discussion
Policy changes, such as those proposed in the ANPRM
in 2011 and the NPRM in 2015, by HHS and OSTP, and
the NIH Genome Data Sharing Policy, have potentially
significant implications for institutions all across the US
conducting biobank research, and for the patients enrolling
in such research. The changes include the recommenda-
tion to require informed consent for research using de-
identified tissue and samples and most clinical data, and
that such consent be obtained in a one-time, open-ended
or “broad” fashion. The only way to study patients’ views of
these policies is to ask them directly, and one way to do so
is through a survey targeting patients most likely to be
impacted by these changes. The eMERGE Network
provided an excellent framework to address these issues as
it included a large population of patients and biobank
participants in a diverse range of health care settings across
the US.
There were several key components that led to our
success in developing and implementing a large survey
across multiple institutions. The first is that the CERC
workgroup was well established and had a long history
of working together on ELSI-related projects through
the eMERGE Network. In addition, the workgroup also
had a history of working both as a full team and with
specialized subgroups to explore specific focus areas
within the CERC venue. Thus, the group was well
equipped to work as a team on this project.
Another key reason the group was successful was that
from the start of the project the CERC Survey work-
group identified key tasks and organized into multi-
disciplinary committees for each task. The CERC work-
group included individuals with a variety of skill sets
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port from the CC was critical to the success as the CC
had a long history of managing all aspects of the
eMERGE Network and had experience managing people,
timelines, and deliverables. Thus the co-chairs and the
CC kept the CERC Survey workgroup on task and
accountable at each step in the process.
There were also clearly a number of challenges.
Obtaining IRB approval at all sites was time consuming.
We decided to obtain IRB approval from each of the
institutions instead of having a central IRB. There were
several reasons for this decision. After conversations
with their various IRBs, some of the sites were
concerned that there would be issues with ceding review
to a central IRB, especially those with limited experience
with reliance agreements. We also felt that obtaining
IRB approval at each institution separately would be
quicker. Because this was a minimal risk study of adults,
it could undergo expedited review instead of full IRB
committee review. The biggest challenge was the coord-
ination of the submission and requirements of individual
institutions. Again, having a committee dedicated to the
IRB submission facilitated the coordination of the IRB
approvals in a timely manner.
Not only did the IRB protocol require approval at each
site, there were other tasks that individuals outside of
the eMERGE CERC workgroup had to undertake. The
major tasks in this category were obtaining BAAs at 9 of
the 11 clinical centers, and finding individuals at each
site who could geocode the sample and transfer the data
to the CC. All institutions had the staff and experience
to obtain and execute BAAs. Geocoding was more of a
challenge as not all institutions had expertise in this area
and it involved working with patient data and large files
that needed to be transferred across sites. In addition,
through geocoding, we intentionally sent surveys to
potential participants who, based on demographic char-
acteristics, are less likely to participate in research,
further limiting our sample.
One challenge was the development of the survey itself.
The large and multi-disciplinary CERC Survey workgroup
provided considerable expertise, but also at times threat-
ened to become unwieldy. Similarly to how the entire
project was organized into tasks, the Survey Development
committee was divided into five sub-subgroups that
focused on each of the domains in our conceptual model.
The Survey Development leader also led the structure of
the survey development into first defining hypotheses,
then domains, and then survey questions. Organizing the
tasks and the Survey Development committee itself were
key to the success of the project.
Finally, another decision that was key to the success of
the survey’s implementation was to use an outside com-
pany to implement the survey. Although 1 site wasunable to use the vendor for mailing, the other 10 were.
Overall, the use of the vendor greatly facilitated the
implementation of the survey. A minor issue was people
mistakenly receiving the survey who had opted out after
the first notification postcard.
We found that some of our assumptions were incor-
rect, including the undeliverable rate. We found the
nondeliverable rate to be lower than anticipated in the
pilot, and therefore decreased the total number of
surveys mailed to 90,000 instead of the original 100,000.
This ended up reducing estimated costs for mailing the
survey. Additionally, choosing to use and coordinate
with 11 different IRBs led to some delays in our study,
due in large part to the different methods for managing
the missed opt-outs at each institution but also to the
different language requirements for approved docu-
ments. Acceptance of a single IRB might have reduced
time but not allowed for local issues to be managed
effectively.
Future studies
As NIH has now adopted a policy for use of a central IRB
for multisite human subjects research (Notice Number:
NOT-OD-16-094), this will impact future studies such as
ours. Further research into the use of a central IRB and it’s
effects on issues such as maintaining local culture, increas-
ing efficiencies, and the use of outside vendors for managing
participant data will help to define the benefits of a central
IRB. In addition, while we made efforts to increase diversity
of participants in our study by stratifying our participant
population prior to mailing surveys, we recognize that this
method may not have been ideal. Also, because our survey
was in English only, we likely decreased responses from
non-English speaking participants. Further research into
methods to increase survey participant diversity through
methods other than linking with census data would further
contribute to knowledge about study design.
Conclusion
Conducting a survey across a number of institutions
with different cultures and practices is a methodological
and logistical challenge. However, with a clear infrastruc-
ture, collaborative attitudes, excellent lines of communi-
cation, and the right expertise, this can be done with
much success.
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